GT Biopharma (GTBP) 10-Q2020 Q3 Quarterly report

Filed: 13 Nov 20, 5:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Abraxane, Adam, age, American, animal, assumed, Avastin, bacterial, began, Berk, Bio, BioScience, biotechnology, Booth, British, Bruce, Celgene, Celularity, certified, chairing, children, CHO, Claimant, classification, Clickstream, coli, College, Cornell, counsel, created, cumulative, decision, degree, disagreement, discovery, doctorate, Dual, earned, East, entity, expand, expedient, faculty, family, fellowship, franchise, Gleevec, global, GoooGreen, Greg, Handelman, Hockey, Hospital, indirect, Intellikine, Interglobal, internship, IVAX, Janex, joining, Kasower, Kinase, League, LLC, mammalian, medicine, member, Michael, monthly, MSA, mTOR, Nominating, noncurrent, nutraceutical, opening, oversaw, person, pivotal, practical, Presbyterian, prometic, relevant, Reserve, residency, School, Squibb, stipend, succeeded, supplement, SV, Theorem, toy, TriKEDual, USA, valid, Venture, Verastem, Vice, Virgin, vivo, Waste, Weill, Wendel, Western, York

Removed: alleging, arose, behalf, certification, Description, duly, executed, Exhibit, existed, Extension, file, herewith, Index, Instance, Label, Linkbase, Liquidated, percent, presentation, reference, registrant, Schema, Supreme, Taxonomy, TetraKE, thereunto, undersigned, XBRL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GTBP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of GT Biopharma, Inc. (the “Company”), for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anthony Cataldo, Chief Executive Officer and Chief Financial Officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, do hereby certify, to my knowledge that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 780(d)); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2020		/s/ Anthony Cataldo
		Anthony Cataldo
		Chief Executive Officer, Chief Financial Officer, Chairman, and Director

A signed original of this written statement required by Section 906 has been provided to GT Biopharma, Inc. and will be retained by GT Biopharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.